Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab DOI Creative Commons
Annunziata Dattola,

Martina Tolone,

Emanuele Amore

и другие.

Dermatology Practical & Conceptual, Год журнала: 2024, Номер unknown, С. e2024204 - e2024204

Опубликована: Июль 31, 2024

The advent of biotechnological drugs has significantly changed the management atopic dermatitis (AD) and approach to moderate-to-severe form this chronic relapsing disease.

Язык: Английский

Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan DOI
Teppei Hagino, Akihiko Uchiyama,

Marina Onda

и другие.

Dermatitis, Год журнала: 2025, Номер unknown

Опубликована: Фев. 20, 2025

Abstract: Background: Real-world data on the effectiveness and safety of lebrikizumab for atopic dermatitis (AD) are limited.

Язык: Английский

Процитировано

1
Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights DOI Creative Commons
Heidi M. Abdel-Mageed

Inflammopharmacology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 7, 2025

Язык: Английский

Процитировано

0
IL-13 inhibition in the treatment of atopic dermatitis – new and emerging biologic agents DOI Creative Commons
Carlos Eduardo Garcez Teixeira, Orhan Yilmaz, Diana Bernardo

и другие.

Journal of International Medical Research, Год журнала: 2024, Номер 52(11)

Опубликована: Ноя. 1, 2024

Atopic dermatitis (AD) is a common, chronic, and recurrent inflammatory skin condition that affects considerable portion of the population, particularly prevalent among children. The development AD influenced by environmental genetic factors, which cause epidermal barrier dysfunction, immune dysregulation, dysbiosis. In there excessive production cytokines. Among cytokines, interleukin (IL)-13 plays major role in pathogenesis AD. Searching for new more selective treatments moderate-to-severe cases important because effect on quality life. Tralokinumab lebrikizumab are IL-13 inhibitors have demonstrated safety efficacy as treatment options phase III trials. approved use Europe USA, while only Europe. Cendakimab, another inhibitor, has shown promising results II trials, providing safe effective outcomes. Eblasakimab, disrupts IL-4 signaling pathways, currently trials following well-tolerated administration I studies. This narrative review aims to outline current state knowledge regarding effectiveness these four biologic agents targeting signaling.

Язык: Английский

Процитировано

3
Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab DOI Creative Commons
Annunziata Dattola,

Martina Tolone,

Emanuele Amore

и другие.

Dermatology Practical & Conceptual, Год журнала: 2024, Номер unknown, С. e2024204 - e2024204

Опубликована: Июль 31, 2024

The advent of biotechnological drugs has significantly changed the management atopic dermatitis (AD) and approach to moderate-to-severe form this chronic relapsing disease.

Язык: Английский

Процитировано

1